9 Comparison of Immediate Breast Reconstruction Outcomes in Patients With and Without Prior Breast Cosmetic Surgical Procedures

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 28

Caroline Fiser, MD1; Sophia Liu, MD1; Neha Goel, MD2; Joshua Kronenfeld, MD1; Wrood Kassira, MD3; John Oeltjen, MD3; Susan Kesmodel, MD2

1DeWitt Daughtry Family Department of Surgery, University of Miami School of Medicine, Miami,FL

2DeWitt Daughtry Family Department of Surgery, Division of Surgical Oncology, University of Miami School of Medicine, Miami, FL

3DeWitt Daughtry Family Department of Surgery, Division of Plastics and Reconstructive Surgery, University of Miami School of Medicine, Miami, FL

Background

The use of skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) with immediate breast reconstruction (IBR) has increased considerably. There is limited information on the complications of IBR in patients with prior breast cosmetic surgical procedures. We compare IBR outcomes in patients undergoing SSM/NSM with and without prior breast cosmetic surgery.

Methods

Patients undergoing mastectomy from January 1, 2017 to December 31, 2019 were selected. Patient characteristics, surgical approach, and complication rates were compared between mastectomy and IBR cases on breasts with and without prior cosmetic surgical procedures. Binary logistic regression analysis was performed to identify factors associated with complications and reconstruction loss.

Results

A total of 956 mastectomies were performed in 697 patients, with IBR performed for 546 mastectomies in 352 patients. There were 189 patients who had bilateral mastectomy, 158 had unilateral mastectomy, and 5 had 2 unilateral mastectomies at different times (10 total mastectomies). The median age was 51 years (range, 19-83 years); 45.7% of patients were younger than 50 years; 28.9% received neoadjuvant systemic therapy; and 62.6% of mastectomies were performed for breast cancer. There were 95 mastectomies (17.4%) performed on breasts with prior cosmetic surgical procedures and 451 (82.6%) without. The NSM procedures were more commonly performed for breasts with prior cosmetic surgery (P < .001). Complications occurred after 75 mastectomies (13.7%) and reconstruction loss in 31 (5.7%). On multivariable analysis, NSM (HR, 2.16; 95% CI, 1.19-3.94) was associated with an increased risk of any complication, while NSM (HR, 2.70; 95% CI, 1.13-6.43) and direct to implant reconstruction (HR, 2.62; 95% CI, 1.14-6.02) were associated with reconstruction loss. Prior breast cosmetic surgical procedures were not associated with an increased risk of complications (HR, 1.05; 95% CI, 0.53-2.06) or reconstruction loss (HR, 1.24; 95% CI, 0.48-3.17).

Conclusion

In this analysis of mastectomy and IBR, prior breast cosmetic surgical procedures were not associated with an increased risk of complications or reconstruction loss. In patients with prior breast cosmetic surgical procedures undergoing mastectomy, IBR may be safely performed.

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content